Literature DB >> 15251128

The role of CD30 in the pathogenesis of haematopoietic malignancies.

Aymen Al-Shamkhani1.   

Abstract

CD30, a member of the tumour necrosis factor receptor superfamily, is overexpressed by malignant cells of Hodgkin's lymphoma and by anaplastic large cell lymphoma. CD30 overexpression has been attributed, at least in part, to constitutive expression of JunB, a transcription factor belonging to the AP-1 family that binds to the CD30 promoter. Overexpression of CD30 in Hodgkin's lymphoma cells is thought to result in ligand-independent signaling, leading to activation of nuclear factor-kappaB and survival of the malignant cells. In anaplastic large cell lymphoma, CD30 triggering induces growth arrest and, under certain circumstances, cell death. Finally, transmembrane signalling by CD30 might be regulated by a soluble form of CD30 that is released by proteolytic cleavage of membrane-anchored CD30.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251128     DOI: 10.1016/j.coph.2004.02.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  15 in total

Review 1.  Immunotherapies for Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard F Ambinder
Journal:  Crit Rev Oncol Hematol       Date:  2007-11-19       Impact factor: 6.312

Review 2.  Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.

Authors:  Chad Tang; Micha Drukker
Journal:  Semin Immunopathol       Date:  2011-04-11       Impact factor: 9.623

Review 3.  Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

4.  Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.

Authors:  Eva Geissinger; Petra Sadler; Sabine Roth; Tina Grieb; Bernhard Puppe; Nora Müller; Peter Reimer; Claudia S Vetter-Kauczok; Jörg Wenzel; Irina Bonzheim; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Andreas Rosenwald
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

5.  CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 cases.

Authors:  Meghna Alimchandani; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 May-Jun

Review 6.  Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Authors:  Aiko Nagayama; Leif W Ellisen; Bruce Chabner; Aditya Bardia
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

7.  A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Otoniel Martinez-Maza; Martin M Oken; William Hocking; Wen-Yi Huang; Dalsu Baris; Betty Conde; Nathaniel Rothman
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

Review 8.  Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.

Authors:  Chad Tang; Irving L Weissman; Micha Drukker
Journal:  Methods Mol Biol       Date:  2013

Review 9.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

10.  Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling.

Authors:  Sarah L Buchan; Aymen Al-Shamkhani
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.